HHS & Healthcare Contracts Intelligence — July 23, 2026

IAVI Inc. received a $95.6M obligation from BARDA/HHS for Marburg and Sudan ebolavirus vaccine development. The firm-fixed-price structure transfers cost overrun risk to IAVI, a nonprofit, creating a neutral signal for public investors due to limited direct equity upside and high execution risk.

IAVI's firm-fixed-price contract for R&D (NAICS 541714) carries high performance risk. As a nonprofit, IAVI has limited financial buffers to absorb cost overruns on vaccine development, which could delay milestones and jeopardize future option exercises.

This single $95.6M contract represents 100% of the digest's total obligation, creating extreme concentration risk on one award and one recipient (IAVI) for this analysis period.

The $166.9M ceiling and multi-year performance period (through 2028) provide a long-term revenue stream for IAVI. Continued government commitment to filovirus vaccine development, as evidenced by this award, could lead to option exercises and additional funding.

The $95.6M IAVI contract demonstrates continued HHS/BARDA investment in biodefense vaccines, specifically for filoviruses (Marburg and Ebola). This aligns with post-pandemic preparedness priorities.

{"entity"=>"IAVI Inc.", "reason"=>"IAVI's performance on this fixed-price R&D contract will determine future option exercises and potential subawardee disclosures.", "trigger"=>"BARDA option exercise announcements; IAVI milestone reports"}